Overview
- BD will establish Neopak glass prefillable syringe production in Columbus, Nebraska, with supply targeted to begin in mid‑2026.
- The investment includes $100 million for Neopak manufacturing and $10 million to enhance cannula capabilities at the site.
- Approximately 120 new jobs are expected at the Columbus facility, building on a separate August 2025 expansion of prefilled flush syringe output.
- Neopak syringes come in 1 mL and 2.25 mL formats, support high‑viscosity formulations, and are designed to integrate with autoinjectors for clinic and at‑home use.
- BD frames the expansion as strengthening U.S. supply‑chain resilience after prior concerns around China‑made syringes and as part of a plan to invest more than $2.5 billion in U.S. manufacturing over five years.